Staying on track: a cluster randomized controlled trial of automated reminders aimed at increasing human papillomavirus vaccine completion

Vaccine. 2014 May 1;32(21):2428-33. doi: 10.1016/j.vaccine.2014.02.095. Epub 2014 Mar 13.

Abstract

Objectives: To evaluate whether automated reminders increase on-time completion of the three-dose human papillomavirus (HPV) vaccine series.

Methods: Ten reproductive health centers enrolled 365 women aged 19-26 to receive dose one of the HPV vaccine. Health centers were matched and randomized so that participants received either routine follow-up (control) or automated reminder messages for vaccine doses two and three (intervention). Intervention participants selected their preferred method of reminders - text, e-mail, phone, private Facebook message, or standard mail. We compared vaccine completion rates between groups over a period of 32 weeks.

Results: The reminder system did not increase completion rates, which overall were low at 17.2% in the intervention group and 18.9% in the control group (p=0.881). Exploratory analyses revealed that participants who completed the series on-time were more likely to be older (OR=1.15, 95% CI 1.01-1.31), report having completed a four-year college degree or more (age-adjusted OR=2.51, 95% CI 1.29-4.90), and report three or more lifetime sexual partners (age-adjusted OR=3.45, 95% CI 1.20-9.92).

Conclusions: The study intervention did not increase HPV vaccine series completion. Despite great public health interest in HPV vaccine completion and reminder technologies, completion rates remain low.

Trial registration: ClinicalTrials.gov NCT01343485.

Keywords: Completion; Human papillomavirus (HPV) vaccine; Information technology; Reminder-recalls.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Humans
  • Immunization Schedule*
  • Papillomavirus Vaccines / administration & dosage*
  • Patient Compliance / statistics & numerical data*
  • Prospective Studies
  • Reminder Systems*
  • Young Adult

Substances

  • Papillomavirus Vaccines

Associated data

  • ClinicalTrials.gov/NCT01343485